Experts Debate Weight-Loss Controversies
Experts at the Obesity Medicine 2026 conference discussed various weight-loss controversies, including the use of GLP-1 drugs and microdosing. The debate highlighted differing opinions on the effectiveness and safety of microdosing compared to standard dosing. Additionally, the panel addressed whether bariatric surgery or medication should be prioritized for patients with class 2 or 3 obesity.
- ▪The conference featured discussions on the appropriateness of starting GLP-1 drugs at lower doses.
- ▪Microdosing is gaining traction, but experts are divided on its routine use in practice.
- ▪There is a need for further studies to define microdosing and its potential benefits.
Opening excerpt (first ~120 words) tap to expand
Does starting GLP-1 drugs below approved doses make sense? Should patients with class 2 or 3 obesity be offered medications or bariatric surgery first? Is it acceptable to use hormone replacement therapy (HRT) as a weight-loss intervention? Do patients lose muscle mass or lean tissue when they shed pounds with GLP-1s? These were among the controversies addressed in a packed and lively session at Obesity Medicine 2026, held by the Obesity Medicine Association (OMA) in San Diego. The debates were engaging and thought-provoking.Microdosing: What Does It Mean?Microdosing — treating patients on doses (usually lower) or regimens (usually less often) outside of those studied in clinical trials — is gaining traction.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
